IRIDEX Corp
NASDAQ:IRIX
Net Margin
IRIDEX Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
IRIDEX Corp
NASDAQ:IRIX
|
16m USD |
-15%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
239B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
187.5B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
153.7B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
148.1B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.3B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.5B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.2B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.6B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.8B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
272.6B CNY |
31%
|
IRIDEX Corp
Glance View
IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company is headquartered in Mountain View, California and currently employs 119 full-time employees. The Company’s laser consoles products consist of Glaucoma, which includes Cyclo G6 laser and delivery devices used for the treatment of glaucoma; Medical Retina product, which includes IQ 532 Laser and IQ 577 Laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases, and its PASCAL Synthesis Photocoagulator for the treatment of retinal diseases; Surgical Retina, which includes OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. Its laser probes products consist of Glaucoma, which include MicroPulse P3 Probe, G-Probe and G-Probe Illuminate, and Surgical Retina probes, which include EndoProbe family of products used in vitrectomy procedures.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on IRIDEX Corp's most recent financial statements, the company has Net Margin of -14.6%.
You don't have any saved screeners yet